2009 Annual Meeting | Clinical Research Methods II

Date Monday 04/27/09

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Karl D. Kieburtz, MD

Topic(s)

Learning Objectives Participants should have more advanced knowledge of specialized clinical trial designs, and the use of biomarkers and biospecimens from clinical trials.

CME Available No CME available

Core Competencies Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Academician

Event Timeline
02:15 PM - 03:00 PM		Phase 2 and the Continual Reassessment Method George Howard, PhD
03:00 PM - 03:45 PM		Implementation Trials - the Second Translation Mathew J. Reeves, PhD, BVSc
03:45 PM - 04:00 PM		Break
04:00 PM - 04:45 PM		Biomarkers in Clinical Trials Andrew D. Siderowf, MD
04:45 PM - 05:30 PM		Special Concerns in Clinical Studies Using Biological Specimens: Consent, Privacy, and Intellectual Property Edward Goldman, JD
05:30 PM - 05:45 PM		Discussion

Faculty Disclosures
George Howard, PhD	Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer.
Edward Goldman, JD	No disclosure on file
Andrew D. Siderowf, MD	Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for askbio. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for capsida. Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parkinson Study Group. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theravance. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurogastrix. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alerity. Dr. Siderowf has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clintrex. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase. Dr. Siderowf has a non-compensated relationship as a Scientific Advisory Board with NeuroPacs that is relevant to AAN interests or activities.
Mathew J. Reeves, PhD, BVSc	Mathew J. Reeves, PhD, BVSc has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association.
Karl D. Kieburtz, MD	Dr. Kieburtz has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Kieburtz has stock in Clintrex Research Corp. Dr. Kieburtz has stock in Hoover Brown. An immediate family member of Dr. Kieburtz has stock in Hoover Brown. Dr. Kieburtz has stock in Safe Therapeutics. The institution of Dr. Kieburtz has received research support from NIH. The institution of Dr. Kieburtz has received research support from Michae J Fox Foundation.

��ɫ��

��ɫ��